2016 NATIONAL OPAT CONFERENCE

Transcription

1 2016 NATIONAL OPAT CONFERENCE ICC BIRMINGHAM, 8TH-9TH DECEMBER 2016 DELEGATE BROCHURE #OPAT16

2

3 CONTENTS 3 Welcome Letter Floorplan Information Agenda - 8th November Agenda - 9th November Conference Speakers Notes Conference Sponsors Poster Abstracts CPD / CERTIFICATE OF PARTICIPATION Certificates will be issued by within 5 working days of the Conference. The event has attracted 9 CPD points.

4 4 WELCOME LETTER Welcome to the 2016 UK OPAT Initiative National Conference. We are delighted to welcome you to this two day conference on Outpatient Parenteral Antimicrobial Therapy (OPAT). The UK OPAT initiative is a multi-stakeholder project that supports, guides and encourages the establishment of standardised OPAT services throughout the UK wherever the clinical need may exist. This meeting is bringing together nearly 300 OPAT experts and we hope that you take the opportunity to share expertise, discuss success stories and learn about upcoming challenges in the OPAT setting. We are delighted to welcome a broad mix of stakeholders from many centres across the UK who are looking to establish, strengthen or extend OPAT services. The conference has been organised with a number of key objectives in mind that include: Defining new pathways for early discharge and admission avoidance for patients with infection Commencing discussions around the establishment of a nursing network for OPAT The value of OPAT in complex conditions BSAC is very grateful to the range of companies present for their support of the conference which enables us to maintain registration fees at a minimum. We would encourage you, if you feel able, to please support our sponsors by visiting their stands during the networking breaks. We very much hope that you enjoy the conference. Professor Dilip Nathwani OBE President BSAC

5 FLOORPLAN 5 Main Entrance PWA BSAC SPONSORS 1 Basilea 2 Fresenius Kabi & Calea 3 Lloyds Pharmacy Clinical Homecare 6 Astellas 7 MSD 8 MSD 9 CME Medical 10 3M & Vygon 11 Bard 12 Bard 13 Cardiome 14 Baxter 15 Pfizer PWA Poster walk area The portrait photographer is available in booth 5 and all registered attendees are entitled to a FREE headshot photograph.

6 6 INFORMATION Function Main Conference Session Breakout session Refreshments & Posters Exhibition Lunch Cloakroom Room Hall 5 Hall 7 Hall 4 Hall 4 Hall 4 Ground Floor Conference admission Admission to conference is by delegate badge only. Please note that delegates are expected to wear name badges at all times. Poster walks and free papers Posters will be presented in the Exhibition Hall (Hall 4) by those delegates who have successfully had their scientific abstracts accepted for inclusion at conference. Catering Refreshments and lunches will be served in the main Exhibition Hall (Hall 4) during the designated break times. Cloakroom The Cloakroom for all visitors is located on the ground floor of the ICC and there is a small charge. Mobile phones Please ensure that all mobile phones are switched off or muted during scientific sessions. Where possible, please make and take your calls in common areas in the venue, away from conference rooms. Liability No responsibility whatsoever will be taken by the meeting, conference secretariat or the ICC for injury or damage to persons or property during the conference. Event Coordinators Pharmatologists Ltd, Ely, Cambs

7 AGENDA - 8TH NOVEMBER Welcome and Opening Remarks Dilip Nathwani, OBE, BSAC President 0940 How can OPAT help deliver the NHS Five Year Forward View? Philip Howard, Consultant Antimicrobial Pharmacist, Leeds Teaching Hospitals NHS Trust, Leeds PLENARY SESSION: Clinical challenges in OPAT Chair, Dilip Nathwani, OBE, BSAC President 1010 Endocarditis Jonathan Sandoe, University of Leeds and Leeds Teaching Hospitals NHS Trust, Leeds 1030 Spinal Infections Neil Ritchie, Clinical Lecturer in Infectious Diseases, Queen Elizabeth University Hospital, Glasgow 1050 Paediatrics - a special population? Sanjay Patel, Consultant Paediatrician, Southampton Children s Hospital, Southampton 1115 REFRESHMENTS AND NETWORKING PLENARY SESSION: Invited papers Chair, Andrew Seaton, Consultant Physician, Queen Elizabeth University Hospital, NHS Greater Glasgow and Clyde 1145 Clinical efficacy, cost-analysis and patient acceptability of outpatient parenteral antibiotic therapy (OPAT): a decade of Sheffield OPAT service Chris Oyewole Durojaiye, Locum Consultant Physician, Royal Hallamshire Hospital, Sheffield 1200 A re- audit evaluating the management of OPAT bronchiectasis patients against current BTS guidelines Heather Boniface, F2-Paediatrics, Princess Royal Hospital, Telford 1215 Success of an outpatient parenteral antimicrobial therapy (OPAT) programme in a large UK paediatric hospital David Porter, Consultant in Paediatric Infectious Diseases, Alder Hey Hospital, Liverpool 1230 Self-administration of intravenous antibiotics for OPAT Emma Nickerson, Associate Specialist in Infectious Disease, Addenbrookes, Cambridge

8 8 AGENDA - 8TH NOVEMBER LUNCH AND POSTER VIEWING 1400 PLENARY SESSION: Dalbavancin - The data, the patients and the practical considerations Sponsored by Cardiome Chair: Dilip Nathwani, OBE, Dundee WORKSHOPS Workshop one: Treatment of skin and soft tissue infections in the ambulatory setting - the Nottingham experience LOCATION: HALL 5 Chair: Elizabeth Hart, Infectious Disease and Acute Medicine Physician, Nottingham Univerisity Hospitals Trust 1445 Learning outcome: Examining how to choose the right agent in the ambulatory care setting, including a review of licensed agents and drivers for prescribing - cost versus convenience versus stewardship versus stability Susan Snape, Consultant Microbiologist, Nottingham University Hospitals, Nottingham, Sarah Williams, Deputy Lead Specialist Nurse, Nottingham University Hospitals, Nottingham Tim Hills, OPAT Pharmacist, Nottingham University Hospitals, Nottingham Elizabeth Hart, Infectious Disease and Acute Medicine Physician, Nottingham University Hospitals, Nottingham Workshop two: Community initiated OPAT services - Admission Avoidance LOCATION: HALL 7 Chair: Sharon Bamber, OPAT Service Lead, Wirral University Teaching Hospital NHS, Merseyside John Cunniffe, Consultant Microbiologist, Wirral University Teaching Hospital NHS, Merseyside 1445 Learning outcomes: Examining key factors in establishing admission avoidance services through safe, competency led services and appropriate patient selection Sharon Bamber, OPAT Service Lead, Wirral University Teaching Hospital NHS, Merseyside John Cunniffe, Consultant Microbiologist, Wirral University Teaching Hospital NHS, Merseyside 1545 REFRESHMENTS AND POSTER VIEWING

9 AGENDA - 8TH NOVEMBER PARALLEL SESSIONS SESSION ONE: The challenges of IV and oral therapies in the OPAT setting LOCATION: HALL 5 Chair: Mark Gilchrist, Consultant Pharmacist in Infectious Diseases, Imperial College Healthcare NHS Trust, London 1615 IVOST: principles and practice in OPAT Andrew Seaton, Consultant Physician, Queen Elizabeth University Hospital, NHS Greater Glasgow and Clyde 1635 Oral Versus Intra-venous Antibiotic Treatment for Bone and Joint Infections Matthew Scarborough, Infectious Diseases Consultant, Oxford University Hospitals NHS Trust, Oxford 1655 Resurgence of older oral therapies in OPAT Carolyn Hemsley, Consultant ID and Microbiology, Guys and St Thomas s Hospital, London 1715 Panel discussion SESSION TWO: Managing Vascular Access - facilitated by IVTEAM LOCATION: HALL 7 Chair: Andrew Jackson, IV Nurse Consultant, The Rotherham NHS Foundation Trust, Rotherham 1615 Introduction: Tip location, CLABSI, Midlines and Passports Andrew Jackson, IV Nurse Consultant, The Rotherham NHS Foundation Trust, Rotherham 1620 Infection Prevention and Vascular Access Martin Kiernan, Visiting Clinical Fellow, University of West London - GAMA Healthcare, London 1635 Vessel Health and Preservation Framework Tim Jackson, Consultant Anaesthetist & Intensivist at Calderdale & Huddersfield NHS Foundation Trust, Huddersfield 1655 ECG PICC Tip Location Gemma Oliver, Nurse Consultant Integrated IV Care at East Kent Hospitals University NHS Foundation Trust, Kent 1715 Panel Discussion 1730 WELCOME DRINKS AND NETWORKING

10 10 AGENDA - 9TH NOVEMBER Breakfast refreshments PLENARY SESSION: Clinical lessons - invited papers Chair: Mark Gilchrist, Consultant Pharmacist in Infectious Diseases, Imperial College Healthcare NHS Trust, London 0800 Clinical efficacy of daily parenteral infusions of meropenem and ampicillin in the OPAT setting James Pollard, Clinical Director, Hospital in the Home, Victoria, Australia 0815 Instructive Endocarditis Case Jonathan Sandoe, Associate Clinical Professor/Honorary Consultant Microbiologist, University of Leeds and Leeds Teaching Hospitals NHS Trust, Leeds 0830 A Case of Unintended Consequences lessons to be learned Beth White, Queen Elizabeth University Hospital, Glasgow 0845 Staphylococcus aureus Bacteraemia & optimal OPAT management - doing the right thing isn t always easy! Eoghan de Barra, Consultant Infectious Diseases, Imperial College Healthcare Trust, London PLENARY SESSION: Antimicrobial Stewardship and OPAT: Special populations Chair, Andrew Seaton, Consultant Physician, Queen Elizabeth University Hospital, NHS Greater Glasgow and Clyde 0900 Treating MDR Negatives in OPAT Fiona Robb, Antimicrobial Pharmacist, NHS Greater Glasgow and Clyde, Glasgow 0925 Paediatric OPAT: an Australasian approach 0950 Q&A Penelope Bryant, Australasian Paediatric Antimicrobial Stewardship Group, Australia

11 AGENDA - 9TH NOVEMBER PARALLEL SESSIONS SESSION ONE: Financial considerations in securing and extending OPAT services LOCATION: HALL 5 Chair: Sanjay Patel, Consultant Paediatrician, Southampton Children s Hospital, Southampton 1000 Proving cost effectiveness in OPAT - what a commissioner needs to know Sue Snape, Consultant Microbiologist, Nottingham University Hospitals, Nottingham 1025 Funding pathways for OPAT 1050 Q&A Achyet Guleri, Clinical Microbiologist, Blackpool SESSION TWO: Interactive Nursing Forum: Lessons from a regional service LOCATION: HALL 7 Chair: Carole Fry, Strategic Lead AMR Programme, Public Health England 1000 Community practice Kate Owen, District Nurse Community IV Team Leader, Dudley Group of Hospitals NHS Trust, West Midlands 1010 Acute practice Gemma Oliver, Nurse Consultant IV Care, East Kent Hospital University NHS Trust, Kent 1020 Establishing a regional the West Midland IV Forum Kate Owen, District Nurse Community IV Team Leader, Dudley Group of Hospitals NHS Trust, West Midlands 1030 Open floor discussion - should we establish a national forum? 1055 Next steps and close 1100 REFRESHMENTS AND POSTER VIEWING 1130 PLENARY SESSION: Driving efficiency in pathway design through patient self-administration Sponsored by Baxter Healthcare Ltd Ann Cole, Baxter Healthcare Ltd

12 12 AGENDA - 9TH NOVEMBER 2016 PLENARY SESSION: Research, policy and data - driving the clinical and nursing agenda Co-Chair, Andrew Seaton, Consultant Physician, Queen Elizabeth University Hospital, NHS Greater Glasgow and Clyde Co-Chair, Mark Gilchrist, Consultant Pharmacist in Infectious Diseases, Imperial College Healthcare NHS Trust, London 1215 NIHR Summary of OPAT work Jane Minton, Consultant in Infectious Diseases, Leeds Teaching Hospitals, Leeds 1235 Revised EPIC3 guidelines impact on OPAT Kate Owen, District Nurse Community IV Team Leader, The Dudley Group NHS Foundation Trust, Dudley 1255 Drug stability - why open access publication of stability data is essential Mark Santillo, Regional Quality Assurance Officer, Torbay & South Devon NHS Foundation Trust, Torquay 1315 Panel discussion 1335 CLOSING REMARKS - Where next for the OPAT in the UK? Mark Gilchrist, Consultant Pharmacist in Infectious Diseases, Imperial College Healthcare NHS Trust, London

13 13 www The Role of Vaccines and Diagnostics in Reducing AMR www www

14 14 SPEAKER BIOGRAPHY Sharon Bamber Clinical Scientist (Microbiology & Infection Control) OPAT Service Manager, Wirral University Teaching Hospital NHS Foundation Trust, Merseyside Sharon has over 25 years experience working in the field of medical microbiology within the NHS, the majority of which has been spent working within clinical laboratories in the North West of England. Her current role utilises the clinical knowledge and managerial skills of a Clinical Scientist to enable the development of a new service incorporating best practice in infection control and antimicrobial stewardship. PRESENTATION DATE & TIME 8th December Chair: Session One - Financial considerations in securing and extending OPAT services 8th December Learning outcomes: Examining key factors in establishing admission avoidance services through safe, competency led services and appropriate patient selection

15 SPEAKER BIOGRAPHY 15 Eoghan de Barra Consultant in Infectious Diseases, Imperial College Healthcare NHS Trust, London Eoghan de Barra received his medical degree in Dublin and proceeded to gain specialist training in Infectious Diseases and General Medicine in Ireland and South Africa. In 2011 he took a post as research fellow and lecturer in the department of Tropical Medicine and International Health at the Royal College of Surgeons in Ireland, Dublin and conducted malaria vaccine research work in Dublin and University of Oxford. In parallel, he worked as a consultant physician in the department of Infectious Diseases at Beaumont Hospital, Dublin, Ireland s national neurosurgical centre. In 2014 he moved to London to work at Imperial College Healthcare NHS Trust as a Consultant in Infectious Diseases, where he is the clinical lead for the OPAT programme. PRESENTATION DATE & TIME 9th December Staphylococcus aureus Bacteraemia & optimal OPAT management - doing the right thing isn t always easy!

16 16 SPEAKER BIOGRAPHY Penelope Bryant Infectious diseases Paediatrician, Royal Children s Hospital, Melbourne, Australia A/Prof Penelope Bryant is an infectious diseases paediatrician and researcher who trained in Australia and the UK and who now works at the Royal Children s Hospital in Melbourne. She is passionate about getting children home from hospital and leads the biggest paediatric acute home care service in Australasia. Her publications provide evidence for the use and misuse of IV antibiotics in hospital and at home and her research aims to discover how we can improve our provision of antibiotics for children. PRESENTATION DATE & TIME 9th December Paediatric OPAT: an Australasian approach

17 SPEAKER BIOGRAPHY 17 John Cunniffe Consultant in Medical Microbiology, Wirral University Teaching Hospital NHS Foundation Trust, Merseyside John Cunniffe has worked at Wirral University Teaching Hospital since During this period he has served as head of department and clinical lead for the joint laboratory project. He is currently Infection Control doctor for the organisation, and is actively engaged in antimicrobial stewardship and sepsis management initiatives. He has been involved in the Wirral OPAT project from the outset, sits on the steering group, and supports the weekly MDT review. PRESENTATION DATE & TIME 8th December Chair: Session One - Financial considerations in securing and extending OPAT services 8th December Learning outcomes: Examining key factors in establishing admission avoidance services through safe, competency led services and appropriate patient selection

18 18 SPEAKER BIOGRAPHY Chris Oyewole Durojaiye Consultant Physician in Infectious Diseases and Tropical Medicine, Department of Infection and Tropical Medicine, Royal Hallamshire Hospital, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield Dr. Chris Oyewole Durojaiye is a Consultant Physician in Infectious Diseases and Tropical Medicine at Royal Hallamshire Hospital, Sheffield, United Kingdom. He is also a Honorary Senior Clinical Lecturer at the University of Sheffield. Dr Durojaiye completed his specialty training in infectious diseases and medical microbiology in Cardiff. His special interests include outpatient parenteral antimicrobial therapy (OPAT), viral hepatitis and tropical infections. PRESENTATION DATE & TIME 8th December Invited papers Paper: Clinical efficacy, cost-analysis and patient acceptability of outpatient parenteral antibiotic therapy (OPAT): a decade of Sheffield OPAT service

19 SPEAKER BIOGRAPHY 19 Mark Gilchrist Consultant Pharmacist in Infectious Diseases at Imperial College Healthcare NHS Trust, London Mark Gilchrist is Consultant Pharmacist in Infectious Diseases at Imperial College Healthcare NHS Trust, and Honorary Senior Lecturer at Imperial College, London. He is immediate past chair of the UK Clinical Pharmacy Association Pharmacy Infection Network (UKCPA PIN), co-chair of the British Society for Antimicrobial Chemotherapy (BSAC) UK Outpatient Parenteral Antimicrobial Therapy (OPAT) Initiative and a spokesman for the Royal Pharmaceutical Society on antimicrobials. Mark trained in Scotland before moving to London to concentrate on a career within infection. He has particular interests in antimicrobial stewardship strategies including OPAT, tuberculosis and critical care. Postgraduate education includes an MSc and non-medical independent prescribing status. He has delivered many lectures and workshops on antimicrobial stewardship both at national and international level and has published around his areas of interest. He was awarded Faculty Fellow of the Royal Pharmaceutical Society in 2013, elected onto BSAC council in 2014 and was a member of the working group that reviewed and developed the 2015 Public Health England Start Smart then focus stewardship toolkit. PRESENTATION DATE & TIME 8th December Chair: Session one: The challenges of IV and oral therapies in the OPAT setting 9th December Chair: PLENARY SESSION: Clinical lessons - Invited papers 9th December Chair: PLENARY SESSION: Research, policy and data - driving the clinical and nursing agenda 9th December CLOSING REMARKS - Where next for the OPAT in the UK?

20 20 SPEAKER BIOGRAPHY Achyut Guleri Consultant Clinical Microbiologist & Clinical Director, Pathology Services, Blackpool Teaching Hospitals NHS Foundation Trust, Hon. Senior Clinical Lecturer, University of Central Lancashire Dr Achyut Guleri is a Consultant Clinical Microbiologist and Clinical Director of Laboratory Medicine at Blackpool Teaching Hospitals NHS Foundation Trust, and Honorary Senior Clinical Lecturer at the University of Central Lancashire. He is also Lead Microbiologist for Lancashire Cardiac Centre, and strategic clinical lead for community/home IV therapy service (OPAT). His special interests include clinical mycology; patient safety; healthcare associated infections and antibiotic stewardship; quality, innovation, productivity and prevention (QIPP) and service development; transformational projects; and antibiotic resistance. Dr Guleri studied at the Medical School, University of Rajasthan in India. He remained in the faculty of the Department of Medical Microbiology at SMS Medical School & Hospital, Jaipur, India for 9 years before accepting a position as Head of Clinical Mycology, Dammam Central Hospital for Eastern Province, Saudi Arabia. In 2006, Dr Guleri joined Blackpool Teaching Hospitals NHS Foundation Trust. PRESENTATION DATE & TIME 9th December Funding pathways for OPAT

21 SPEAKER BIOGRAPHY 21 Elizabeth Hart Consultant in Infectious Diseases and Acute Medicine, Department of Infectious Diseases, Nottingham University Hospitals, Nottingham Liz Hart is a Consultant in Acute medicine and Infectious Diseases at Nottingham University Hospitals NHS Trust. She has worked within the OPAT (Outpatient Parenteral Antibiotic Therapy) Department since its early days. She uses her wide ranging activities to increase awareness of the OPAT service. This includes increasing the numbers of acute medical patients that are eligible for OPAT with the aim of appropriately managing the patient with multiple co-morbidities safely in the outpatient setting. PRESENTATION DATE & TIME 8th December Chair: Workshop one - Treatment of skin and soft tissue infections in the ambulatory setting - the Nottingham experience 8th December Learning outcome: Examining how to choose the right agent in the ambulatory care setting, including a review of licensed agents and drivers for prescribing - cost versus convenience versus stewardship versus stability.

22 22 SPEAKER BIOGRAPHY Carolyn Hemsley Microbiology and Infectious Disease Consultant, Department of Infection, Guy s and St Thomas NHS Foundation Trust, London Carolyn Hemsley is Clinical Lead and Consultant in Infectious Diseases and Microbiology at Guy s and St Thomas NHS Foundation Trust in London. She studied at Oxford University, completed her specialist training in Oxford and London and completed a PhD on Pneumococcal Virulence factors at Tufts University, Boston in collaboration with Imperial College, London. Appoint as a consultant at GSTT in 2007, she took over as Clinical Lead for Microbiology and Infectious Diseases in In her time as a consultant she has developed a bone infection service at GSTT and in 2009 set up an OPAT service which she continues to lead. Her clinical practice also involves management of infection in the non-hiv immunocompromised supporting Guy cancer centre. She has been involved with BSAC OPAT initiative since inception, PI for OVIVA at GSTT and is a member of UK Clinical Research Infection Group (UKCRIG). PRESENTATION DATE & TIME 8th December Resurgence of older oral therapies in OPAT

23 SPEAKER BIOGRAPHY 23 Tim Hills Lead Pharmacist, Antimicrobials and Infection Control at Nottingham University Hospitals NHS Trust (NUH), Nottingham Tim Hills is Lead Pharmacist, Antimicrobials and Infection Control at Nottingham University Hospitals NHS Trust (NUH). He joined NUH in 1999 and has held a number of posts before becoming the antimicrobial pharmacist in Tim is an active member of the UK Clinical Pharmacist s Association Pharmacy Infection Network and was lead author of The introduction and impact of an HTML based antibiotic guidelines website the winning submission for the inaugural UKCPA Antimicrobial Management Award in He chairs the East Midlands Antimicrobial Pharmacist s Group. His interests include OPAT where he is part of the Nottingham OPAT team and BSAC OPAT Standards committee and the treatment and prevention of Clostridium difficile associated diarrhoea. PRESENTATION DATE & TIME 8th December Learning outcome: Examining how to choose the right agent in the ambulatory care setting, including a review of licensed agents and drivers for prescribing - cost versus convenience versus stewardship versus stability

24 24 SPEAKER BIOGRAPHY Philip Howard Consultant Pharmacist in Antimicrobials, Leeds Teaching Hospitals NHS Trust, AMR Project Lead at NHS-Improvement, Honorary Senior Lecturer at Leeds University, Leeds Philip Howard is a spokesman for the Royal Pharmaceutical Society on Antimicrobials, and for the charity Antibiotic-Action. He was a member of the Dept of Health ARHAI Antimicrobial Stewardship Group that produced the original Start Smart then Focus Antimicrobial Stewardship Guidelines, and the HPA Primary Care Unit which helped produce the RCGP TARGET guidance on Antimicrobial Stewardship in Primary Care. His research interests include Antimicrobial Stewardship, and led the first global hospital Antimicrobial Stewardship survey. He has been involved in AMS education and training across the world. In 2012, he won the GHP/GSK/UKCPA Clinical Leadership Award. He is a committee / council member of: RPS Expert Advisory Group on Antimicrobials UKCPA Pharmacy Infection Group Antibiotic Policies Group of European Society of Clinical Microbiology & Infectious Diseases PRESENTATION DATE & TIME 8th December How can OPAT help deliver the NHS Five Year Forward View?

25 SPEAKER BIOGRAPHY 25 Andrew Jackson IV Nurse Consultant and Director IVTEAM, The Rotherham NHS Foundation Trust Andrew has held a senior IV nurse role since Andrew splits his time between clinical, educational, research and leadership activities. However, the vast majority of his time is occupied with clinical work and leadership activities. In addition, Andrew is the creator and director of IVTEAM.com. Achievements include: Introduction of a hospital-wide vascular access team. Development of an integrated hospital and community IV service. Development of a peripheral IV site monitoring tool the VIP score. Development of peripheral IV bundle. Development of PICC passport. Qualified independent prescriber. Organisational CLABSI rate of 0.3 per thousand catheter days. PRESENTATION DATE & TIME 8th December Chair: Session Two - Managing Vascular Access - facilitated by IVTEAM 8th December Introduction: Tip location, CLABSI, Midlines and Passports

26 26 SPEAKER BIOGRAPHY Dilip Nathwani OBE President, BSAC Consultant Physician in Infectious Diseases and Honorary Professor of Infection at Ninewells Hospital & Medical School, Dundee Professor Dilip Nathwani serves as National Specialty Adviser for Infectious Diseases to the Scottish Government Health Department, Recent Chair of the European Study Group on Antibiotic Policies and is President of the British Society for Antimicrobial Chemotherapy (BSAC). He also held the post of Director of Medical Education for NHS Tayside between 2006 and Professor Nathwani chairs the Scottish Antimicrobial Prescribing Group - Government Funded National Stewardship Programme. He has authored more than 225 peer-reviewed publications and contributed extensively to national and international infection guidelines or policy statements. Professor Nathwani was awarded OBE for contribution to the treatment of infectious diseases in the Queen s the New Year s Honours List in Professor Nathwani spearheaded the establishment of the UK OPAT Initiative in 2009 having a long standing interest in outpatient parentaral therapy. PRESENTATION DATE & TIME 8th December Welcome and Opening Remarks 8th December Chair: PLENARY SESSION - Clinical challenges in OPAT 8th December Chair: Dalbavancin - The data, the patients and the practical considerations

27 SPEAKER BIOGRAPHY 27 Emma Nickerson Associate Specialist in Infectious Diseases, Cambridge University Hospitals NHS Trust, Addenbrooke s Hospital, Cambridge Emma graduated from Cambridge University (UK) and Imperial College London and subsequently undertook a PhD at the Wellcome Unit in Thailand on Defining the burden of morbidity and mortality due to invasive Staphylococcus aureus disease and the impact of drug resistance in Thailand. She currently works at consultant level at Addenbrooke s Hospital, Cambridge specialising in Bone and Joint Infection. In addition to working in Infectious Diseases, Emma forms part of the Bone Infection and OPAT teams as well as being a key member of the hospital s project team tasked with setting up a regional Bone Infection Unit. PRESENTATION DATE & TIME 8th December Self-administration of intravenous antibiotics for OPAT

28 28 SPEAKER BIOGRAPHY Kate Owen District Nurse community IV Team Leader, Dudley Group NHS Foundation Trust, West Midlands Kate has over 21 years of registered nursing experience, 16 of which have been as a District Nurse in Dudley, West Midlands. Five years ago, Kate developed the Community Intravenous Team which encompasses the Oncology Outreach Service and the OPAT Service for Dudley Group NHS Foundation Trust. In 2014, Kate was elected to the BSAC OPAT Standing Committee as a nurse representative and also gained the title of Queen s Nurse for bringing care traditionally given in hospital out into the community. Kate is passionate about providing safe and effective care in the community. She believes that it is essential to support patients and staff to achieve this aim. PRESENTATION DATE & TIME 9th December Interactive session to discuss practical nursing aspects to OPAT 9th December Revised EPIC3 guidelines impact on OPAT

29 SPEAKER BIOGRAPHY 29 Sanjay Patel Consultant in Paediatric Infectious Diseases and Immunology, Southampton Children s Hospital, Southampton Dr Sanjay Patel is a paediatric infectious diseases and immunology consultant working at Southampton Children s Hospital, England. He trained at Cambridge University medical school before completing his paediatric training in London followed by his higher specialist training in paediatric infectious diseases and immunology at St Mary s Hospital London, Great Ormond Street Hospital London and Newcastle Children s Hospital. He has also worked within the field of paediatric HIV and TB in Pietermaritzburg, South Africa. His specific areas of interest are OPAT and antibiotic stewardship. In 2012, he introduced the first paediatric outpatient parenteral antibiotic therapy (p-opat) service in the UK. He led the BSAC p-opat workstream and chaired the joint BSAC / British Paediatric Allergy, Immunology and Infectious Diseases Group p-opat national working group tasked to develop good practice guidelines for the introduction and delivery of p-opat services in the UK, which were published in October He was a member of the NICE antibiotic stewardship guideline development group which published guidelines in He is on the BSAC OPAT standing committee and sits on BSAC council. He is co-lead for the module on antimicrobial stewardship for the ESPID on-line antibiotic management course and runs infectious diseases courses at Imperial College and in Iceland. PRESENTATION DATE & TIME 8th December Paediatrics- A Special Population? 9th December Chair: Session One - Financial considerations in securing and extending OPAT services

30 30 SPEAKER BIOGRAPHY James Pollard Clinical Director, Hospital in the Home, Infectious Diseases Physician Barwon Health, University Hospital Geelong, Victoria, Australia James Pollard is Clinical Director of Hospital in the Home at Barwon Health in Geelong, Australia. James is an Infectious Diseases Physician who has an interest in patient-centred care and de-centralisation of healthcare. James has been Clinical Director of HITH at Barwon Health since 2012, and also has appointments in antibiotic stewardship, HIV medicine, Hepatitis management, clinical infectious diseases and general medicine. PRESENTATION DATE & TIME 9th December Clinical lessons - free papers selected from abstracts Paper: Clinical efficacy of daily parenteral infusions of meropenem and ampicillin in the OPAT setting

31 SPEAKER BIOGRAPHY 31 Fiona Robb Antimicrobial Pharmacist Queen Elizabeth University Hospital, NHS Greater Glasgow & Clyde, Glasgow Fiona Robb is an Antimicrobial Pharmacist at the Queen Elizabeth University Hospital in NHS Greater Glasgow and Clyde. After graduating with a Masters in Pharmacy from Strathclyde University she continued her studies achieving an MSc in Clinical Pharmacy and Independent Prescriber qualification. OPAT is the highlight of her job because of the team approach drawing on each member s expertise and knowledge to overcome the challenges of outpatient therapy and to ensure the best treatment outcomes for the patient. PRESENTATION DATE & TIME 9th December Treating MDR Gram-Negative infections in OPAT

32 32 SPEAKER BIOGRAPHY Neil Ritchie Clinical Lecturer in Infectious Diseases, Queen Elizabeth University Hospital, Glasgow Neil is a Clinical Lecturer in Infectious Diseases at the University of Glasgow and a senior trainee in Infectious Diseases at the Queen Elizabeth University Hospital in Glasgow. He completed his PhD in pneumococcal immunobiology in His clinical interests include antimicrobial stewardship and management of complex post-surgical infection. PRESENTATION DATE & TIME 8th December Spinal Infections

33 SPEAKER BIOGRAPHY 33 Jonathan Sandoe Associate Clinical Professor Medical Microbiology, Hon Consultant University of Leeds, Leeds Teaching Hospitals NHS Trust, Leeds Jonathan Sandoe is Associate Clinical Professor of Medical Microbiology at the University of Leeds and Honorary Consultant Microbiologist at Leeds Teaching Hospitals NHS Trust. He was a founder member of the Leeds Endocarditis Service, a multidisciplinary team which has managed patients with infective endocarditis (IE) at LTHT since He has a longstanding interest in the management and prevention of IE. Since 2002 he has been a member of the British Society for Antimicrobial Chemotherapy Endocarditis Working Party and in 2011 took over as chair. The Working Party has published guidelines concerning the management of IE as well as implantable cardiac electronic device infections. He was a member of the guideline development group for the National Institue for Health and Clinical Excellent (NICE) endocarditis prophylaxis guidelines and a British Heart Valve Society Working Party looking at models of service provision for patients with heart valve disease. PRESENTATION DATE & TIME 8th December Endocarditis 9th December Instructive Endocarditis Case

34 34 SPEAKER BIOGRAPHY Mark Santillo Regional Quality Assurance officer South West England, Torbay & South Devon NHS Foundation Trust, Devon Mark Santillo has over 30 years experience in Pharmaceutical Quality Assurance and Quality control within the NHS, the past 9 years as Regional Quality Assurance Officer within South West England. Currently chair of the NHS Pharmaceutical Research and Development Group, Mark has been involved in the preparation of NHS standards for stability testing and assessment and also in the review of commercial stability studies including for biopharmaceuticals. Mark is an active member of the NHS Pharmaceutical Quality Assurance Committee (currently Vice-Chair) and the Pharmaceutical Aseptic Services Group and has produced guidance in a variety of areas relating to pharmaceutical QA for the NHS. He is also the module director for the Quality Control module of the PTQA course run by the University of Manchester, the NHS Representative on the Joint Pharmaceutical Analysis Group committee and a member of the BP Unlicensed Medicines Expert Advisory Group PRESENTATION DATE & TIME 9th December Drug stability why open access publication of stability date is essential

35 SPEAKER BIOGRAPHY 35 Matthew Scarborough Consultant in Clinical Infection, Oxford University Hospitals NHS Trust, Oxford Matt works in infectious diseases, general medicine and microbiology and is currently the lead physician for the OPAT service in Oxford. Much of his clinical time is spent on the bone infection unit, the main source of referrals to OPAT in Oxford. His research interests include Staph. aureus bacteraemia, orthopaedic infection and the prevention and control of health care associated infections. PRESENTATION DATE & TIME 8th December Oral Versus Intra-venous Antibiotic Treatment for Bone and Joint Infections

36 36 SPEAKER BIOGRAPHY Andrew Seaton Co-Chair, Consultant Physician, Brownlee Centre, Gartnavel General Hospital, Queen Elizabeth University Hospital, NHS Greater Glasgow and Clyde Graduated Aberdeen University in 1989, and then completed specialist training in infectious diseases and general medicine in Dundee in Consultant Physician and Honorary Senior Lecturer in Infectious diseases and General Medicine in Glasgow since Established and lead the NHS Greater Glasgow and Clyde Health Board OPAT service, leads the Antimicrobial Management Team and is chair of the NHS GGC Antimicrobial Committee. Clinical lead on infection management within the Scottish Antimicrobial Prescribing Group. Council member of the British Society of Antimicrobial Chemotherapy and Co-Chair of the BSAC OPAT standing committee. PRESENTATION DATE & TIME 8th December IVOST: principles and practice in OPAT 9th December Chair: Antimicrobial stewardship and OPAT: Special populations 9th December Co-chair: Research, policy and data - driving the clinical and nursing agenda

37 SPEAKER BIOGRAPHY 37 Sue Snape Consultant in Infectious Diseases and Microbiology and lead OPAT consultant, Nottingham University Hospitals NHS Trust, Nottingham Sue Snape is the lead OPAT consultant at Nottingham University Hospitals NHS Trust. She established microbiology liaison with the trauma and orthopaedic teams, diabetic foot service and respiratory teams regarding the use of antimicrobials; and is education lead for Microbiology StRs in Nottingham. She has developed the OPAT service from its inception in 2011 to the current time, now employing 25 staff members. In 2015/16 the service saw 620 patient episodes and saved bed days. One of the chief and ongoing challenges in establishing the service has been the securing of recurrent funding and negotiating service expansion with commissioners. PRESENTATION DATE & TIME 8th December Learning outcome: Examining how to choose the right agent in the ambulatory care setting, including a review of licensed agents and drivers for prescribing - cost versus convenience versus stewardship versus stability 9th December Proving cost effectiveness in OPAT - what a commissioner needs to know

38 38 SPEAKER BIOGRAPHY Beth White Consultant in Infectious Diseases and Acute Medicine, Queen Elizabeth University Hospital, Glasgow Beth White initially studied and trained in Aberdeen and came to Glasgow for specialist training in Infectious Diseases in Throughout her final years in training, and since taking up her Consultant post in Glasgow she has been involved in the Glasgow OPAT service, including IT developments and improving front door OPAT use for SSTIs. PRESENTATION DATE & TIME 9th December Missed dx in OPAT with emphasis on lessons learned e.g. Missed diagnosis in OPAT

39 SPEAKER BIOGRAPHY 39 Sarah Williams Deputy Lead OPAT Specialist Nurse Infectious Diseases Department, Nottingham University Hospitals, Nottingham Sarah Williams is the Deputy Lead Nurse within the OPAT Team at Nottingham University Hospitals. Alongside patient care, she has a keen interest in facilitating teaching sessions with hospital and community staff to ensure that care of IV lines is optimum. Since graduating from The University of Nottingham in October 2010, Sarah spent 18 months at as Staff Nurse on the Infectious Diseases Ward before joining the OPAT Team as a Specialist Nurse in June PRESENTATION DATE & TIME 8th December Learning outcome: Examining how to choose the right agent in the ambulatory care setting, including a review of licensed agents and drivers for prescribing - cost versus convenience versus stewardship versus stability

40 40 NOTES

41 NOTES 41

42 42 NOTES

43 SPONSORS 43 STAND NO. 10 3M Every intravenous (I.V.) site presents the potential for infection, dislodgement, skin damage, and other complications. These incidents can potentially cause patient discomfort and pain, extended hospital stays, additional therapy, and surgical intervention even increased patient mortality. 3M science has delivered unique solutions that give you what you need to protect every I.V. catheter from insertion to removal. Our broad portfolio of high-quality products makes it easy for you to choose and use the right solution: from barrier films to securement devices, antimicrobial dressings and disinfecting caps. We can help you deliver compassionate care with evidence-based products to support patient and clinician safety, help prevent the risks of costly complications, and improve patient satisfaction. STAND NO. 6 ASTELLAS Astellas is a global pharmaceutical company dedicated to improving the health of people around the world. Committed to research in anti-infective care, Astellas is focusing on saving the lives of critically ill patients. Astellas key contacts: Will Goulding Anti Infectives, Brand Manager will.goulding@astellas.com Ruth Rostron Anti Infectives, Brand Manager ruth.rostron@astellas.com Astellas Pharma Ltd, 2000 Hillswood Drive, Chertsey, Surrey KT16 0RS

44 44 SPONSORS STAND NO. 11/12 BARD Bard Access Systems is an innovator and market leader in vascular access devices, creating products that have a positive impact on people s lives. We develop, manufacture and distribute medical devices used by an array of practitioners in gaining access to the cardiovascular system for the purpose of delivering chemotherapy, blood products, antibiotics, drugs or nutrition. Please visit our stand #11-12 to view the Site Rite 8 Ultrasound System with integrated Sherlock 3CG for vessel assessment, real time catheter visualization and ECG for tip confirmation. NICE recommends using Sherlock 3CG tip confirmation system from Bard to help with positioning PICCs. STAND NO. 1 BASILEA Basilea Pharmaceutica Ltd. is headquartered in Basel, Switzerland. It focuses on products that address increasing resistance and non-response to current treatment options in the therapeutic areas of bacterial infections, fungal infections and cancer. The company uses the integrated research, development and commercial operations of its subsidiary Basilea Pharmaceutica International Ltd. to discover, develop and commercialize innovative pharmaceutical products to meet the medical needs of patients with serious and potentially life-threatening conditions.

45 SPONSORS 45 STAND NO. 14 BAXTER Outpatient parenteral antimicrobial therapy (OPAT) offers several advantages to both patients and healthcare providers. It allows the patient to receive their treatment at home, and has been shown to deliver successful outcomes whilst reducing costs. Baxter enables NHS Trusts to realise the benefits of OPAT in a number of ways. Baxter Infusor devices support moving suitable OPAT patients to a self-care model. Additionally we have a Hospital IV Therapy Specialist team that works with NHS nurses to train and support patients, ensuring they are comfortable with the transition from hospital to home and are ready to self-care. With 30 years experience of providing high quality aseptic compounding supported by extensive stability data, we can help you release the burden on you aseptic unit by providing ready-to-use aseptically filled infusor pumps. We can also offer you further support in the provision of OPAT through our homecare service, Baxter at Home. STAND NO. 2 CALEA Calea, part of Fresenius Kabi, is a specialised homecare company with over 25 years of experience in delivering high quality products and services across the UK. We work in partnership with healthcare professionals to provide care packages that meet local requirements and patient needs. We provide a range of home therapy services in collaboration with clinical and commissioning teams to facilitate the patient s journey from hospital to home.

46 46 SPONSORS STAND NO. 13 CARDIOME STAND NO. 9 CME MEDICAL We are CME Medical We believe in making clinical practice safer and more efficient. Our heritage is in developing specialist medical infusion devices and support that improve patient care in hospital, in the community and at home. We consistently explore new ways to support healthcare professionals with our pioneering approach to developing medical technology products, services and training. Kincraig Business Park, Kincraig Road, Blackpool, FY2 0PJ T: F: customersupport@cmemedical.co.uk cmemedical.co.uk

47 SPONSORS 47 STAND NO. 2 FRESENIUS KABI Fresenius Kabi is the leader in infusion therapy and clinical nutrition in Europe. It is focused on the therapy and care of critically and chronically ill patients in both the hospital and home environment. The company develops, manufactures and markets products that offer efficient clinical outcomes combined with a commitment to quality and patient safety. With a corporate philosophy of Caring for Life the company s goal is to improve the patient s quality of life. This means that we continuously strive to develop our specialist skills in the fields of nutrition, infusion therapy, oncology and homecare. In doing so we provide innovative solutions to meet the highest standards of patient care STAND NO. 7/8 MSD Today s MSD is a global healthcare leader working to help the world be well. MSD is a trade name of Merck & Co., Inc., with headquarters in Kenilworth, NJ, USA. Through our prescription medicines, biologic therapies and animal health products, we work with customers and operate in more than 140 countries to deliver innovative health solutions. We also demonstrate our commitment to increasing access to healthcare through farreaching policies, programmes and partnerships. For more information, visit

48 48 SPONSORS STAND NO. 3 LLOYDS PHARMACY CLINICAL HOMECARE We re one of the most experienced providers of clinical homecare in the UK, and we ve been supporting patients in this way since We provide care to more than 36,000 patients in their own home, ranging from straightforward delivery of medication to specialist nursing for complex conditions. We used to be called Bupa Home Healthcare and in July 2016 we were acquired by the Celesio UK group of companies, a leading provider of healthcare services, including LloydsPharmacy. Being part of the Celesio UK group of companies means we are perfectly placed to address the evolving needs of healthcare in the UK. We work in partnership with the NHS, pharmaceutical companies, and private medical insurers. Our range of treatments and conditions includes home parenteral nutrition, chemotherapy, IV antibiotics, enzyme replacement therapy, rheumatoid arthritis, multiple sclerosis and much more. Because we manage the entire end-to-end homecare journey, using our own in-house staff and closely monitored processes, we are able to control and assure safety and quality at every stage from prescription management through to medication delivery and nursing care in patients own homes. We re passionate about what we do and the difference we make to our patients lives. It s this dedication that ensures we constantly deliver outstanding levels of care to our patients. enquiries@lpclinicalhomecare.co.uk

49 SPONSORS 49 STAND NO. 15 PFIZER Today, Pfizer offers patients access to a diverse portfolio of 14 anti-infective and anti-fungal medicines. More than ever, the world needs new approaches to preventing and fighting infections. Pfizer recently joined with over 100 industry partners to sign the Declaration on Combating Antimicrobial Resistance, announced in January at Davos, to call on governments to join industry in taking swift, coordinated action. Pfizer sponsors the most comprehensive global antimicrobial resistance surveillance program in the industry. These programmes provide critical data regarding antibiotic resistance patterns that enable physicians and healthcare providers to make the most appropriate treatment choices for their patients. The goals of these programmes are to provide important information on resistance and to assess antibiotic stewardship. Pfizer routinely sponsors and conducts medical education outreach to healthcare providers through a variety of channels, including medical symposia, to ensure appropriate utilisation of antibiotics and improve infection prevention and control. Pfizer recently supported the British Society for Antimicrobial Chemotherapy and the University of Dundee to launch the Massive Open Online Course (MOOC) on antimicrobial stewardship. Pfizer is proud to sponsor the OPAT Meeting and we look forward to sharing this meeting with you.

50 50 SPONSORS STAND NO. 10 VYGON We are a leading supplier of medical and surgical devices with a reputation for delivering high quality products and excellence in customer service, helping healthcare professionals offer best practice solutions to patients. Our Products Our product ranges extend across many therapeutic specialties, including vascular access, regional anaesthesia, IV management, neonatology and enteral feeding. Our Services We provide complementary training and technical support to customers to promote best practice in-line with current clinical guidelines. T: E: marketing@vygon.co.uk W:

51 POSTER ABSTRACTS 51 NO 1 NO 2 NO 3 NO 4 NO 5 NO 6 NO 7 NO 8 NO 9 HEATHER BONIFACE, F2-PAEDIATRICS, PRINCESS ROYAL HOSPITAL, TELFORD A re- audit evaluating the management of OPAT bronchiectasis patients against current BTS guidelines STEVE COLLINS, LEAD CLINICAL NURSE SPECIALIST IN OPAT, UNIVERSITY COLLEGE LONDON HOSPITALS Leaderflex IV catheters reduce length of inpatient stay and facilitate admission avoidance pathways for OPAT patients CHRIS DUROJAIYE, LOCUM CONSULTANT PHYSICIAN, ROYAL HALLAMSHIRE HOSPITAL, SHEFFIELD Clinical efficacy, cost-analysis and patient acceptability of outpatient parenteral antibiotic therapy (OPAT): a decade of Sheffield OPAT service EMMA NICKERSON, ASSOCIATE SPECIALIST IN INFECTIOUS DISEASE, ADDENBROOKES, CAMBRIDGE Model plastic arm for teaching self-administration of antibiotics for OPAT EMMA NICKERSON, ASSOCIATE SPECIALIST IN INFECTIOUS DISEASE, ADDENBROOKES, CAMBRIDGE Video demonstrations for supporting teaching of self-administration of intravenous antibiotics for OPAT JAMES POLLARD, CLINICAL DIRECTOR, HOSPITAL IN THE HOME Clinical outcomes when treating Injecting Drug Users via OPAT JAMES POLLARD, CLINICAL DIRECTOR, HOSPITAL IN THE HOME Clinical efficacy of daily parental infusions of meropenem and ampicillin in the OPAT Setting DAVID PORTER, CONSULTANT IN PAEDIATRIC INFECTIOUS DISEASES, ALDER HEY HOSPITAL, LIVERPOOL Success of an outpatient parenteral antimicrobial therapy (OPAT) programme in a large UK paediatric hospital TRANPIT SALUJA, CONSULTANT MICROBIOLOGIST, SANDWELL AND WEST BIRMINGHAM HOSPITAL NHS FT OPAT Service: Never event NO 10 TRANPIT SALUJA, CONSULTANT MICROBIOLOGIST, SANDWELL AND WEST BIRMINGHAM HOSPITAL NHS FT 24 hour infusion of piperacillin/ tazobactam delivered via an elastomeric device to bronchiectasis patients: SWBH experience NO 11 TRUPTI PATEL, CONSULTANT MICROBIOLOGIST, UNIVERSITY COLLEGE LONDON HOSPITALS Reduction of carbapenem use in OPAT a realistic CQUIN target?